Clinical Trials Browser

Phase 2 × INDUSTRY × Panitumumab × Clear all

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Cancer Metastatic

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Neoplasm Metastasis, Recurrence

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

Colonic Neoplasms, Exanthema, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Pancreatic Neoplasms

Carcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Kidney Neoplasms

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Prostatic Neoplasms

Clinical Trials

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

SAPPHIRE

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

STEPP

PRECEPT

Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

APPRISE 1

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body